Navigation Links
TheraVasc Releases Phase I Trial Data Demonstrating Safety of Drug in Diabetic Patients
Date:9/20/2011

ting 14 million people in the United States leading to significant pain in the limbs that can ultimately result in amputation. "Based on the safety, circulating half life levels of the drug and blood levels achieved in this study, we believe that chronic use of TV1001 will provide a disease altering benefit to diabetic patients with PAD," said TheraVasc President and CEO, Tony Giordano, Ph.D.  

About TheraVasc

TheraVasc Inc., located in Cleveland, Ohio is dedicated to reducing the risk, cost, and time associated with drug development by focusing on developing repurposed drugs for unserved vascular disease markets. TheraVasc's initial product, TV1001 (an oral formulation of sodium nitrite) targets patient populations with poor blood flow to the extremities, such as those with diabetic leg and foot problems or those with peripheral artery disease.


'/>"/>
SOURCE TheraVasc Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. CEL-SCI Corporation Releases Letter to Shareholders
3. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
4. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
5. Immunosyn Corporation Releases SF-1019 Study Results
6. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
7. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
8. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
9. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
10. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
11. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... novel wearable injector slightly larger than an Oreo cookie may ... prescription drugs in the large doses required to treat a ... and genetic disorders.  An emerging biologic drugs ... to analysts.   Many of these drugs will require a new ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
(Date:1/14/2014)... Jan. 14, 2014   Oligomerix, Inc. , a privately held ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced today ... Valhalla, NY as of January 15, 2014 ... New York Medical College. Oligomerix, which is ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Feb. 28, 2012 Landauer, Inc. (NYSE: LDR) ... quarterly cash dividend of $0.55 per share for the second ... 3, 2012, to shareholders of record on March 9, 2012. ... global provider of technical and analytical services to determine occupational ...
... N.C., Feb. 28, 2012  In an effort to maximize ... and biotech market research leaders must constantly evaluate the ... executives need to understand the optimal balance of external ... productivity in the quickly changing healthcare industry. ...
Cached Medicine Technology:Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups 2
(Date:4/17/2014)... 40 years away from a food shortage that will ... a top scientist at the U.S. Agency for International ... production will be limited on a global scale by ... Fred Davies, senior science advisor for the agency,s bureau ... destabilizing by 2050 as energy issues are today.", Davies, ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... (April 16, 2014) A team that includes scientists from ... Science Center at San Antonio, Johns Hopkins University and St. ... a common fungus to infect the body. , The fungal ... and oral thrush, and is the most common fungal pathogen ...
(Date:4/15/2014)... solved a decades-old medical mystery and in the process have ... which kill about 1.5 million people a year. The researchers say ... drug that has been in use for more than 50 years ... as it is to the microbes it attacks. , A ...
(Date:4/14/2014)... Ford Hospital reached a medical milestone April 3, performing ... way to access the heart. , Henry Ford is ... unique procedure called transcaval valve replacement, which accesses the ... Michigan resident Viola Waller, 80, underwent Henry Ford,s first ...
Breaking Medicine News(10 mins):Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Henry Ford Hospital hits new heart valve surgery milestone 2
... Lomb is one of the leading company which manufactures contact ... serious eye infections in some users. // After ... inspect Bausch & Lomb facilities. There was extensive microbiological testing ... analyze the culprit behind the eye infection. Bausch & Lomb ...
... the wonder enzyme in sepsis increases the bodys vulnerability ... confers strong resistance to sepsis. // ,This ... humans. ,"The results of the study make ... elimination of bacterial pathogens, and that a deficiency allows ...
... it has been categorized in A,B and C. A biological ... call for special actions by the pubic health system. // ... at Rockefeller University which suggests that a newly discovered protein ... areas in which anthrax spores have been released. ...
... to the hospitals in the twin cities,following symtoms of cough, ... flu infection. // ,With this , the total ... ministry has confrimed that no H5N1 strain has been detected ... culled ever since the outbreak. ,The suspected bird ...
... behind the aggressive head and neck cancer was unveiled by ... // It is a highly malignant form of cancer ... triple interaction between CD44, hyaluronan (HA), and LARG. CD44 is ... a variety of cellular functions. Hyaluronan (HA) is a complex ...
... the more evident after this pathbreaking study. Overeating and ... children accoding to the study. // ,This study ... trend of childhood obesity, which is perhaps a reminder to ... advertisments targeting children. ,Nearly 5,407 students from 90 public ...
Cached Medicine News:Health News:Sepsis risk increased due to the absence of one key enzyme 2Health News:A Detail Analysis of Head and Neck Cancer 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: